Showing 271 - 280 of 503
GDP per capita is usually used to proxy for the quality of life of individuals living in different countries. Welfare is also affected by quantity of life, however, as represented by longevity. This paper incorporates longevity into an overall assessment of the evolution of cross-country...
Persistent link: https://www.econbiz.de/10005573295
Persistent link: https://www.econbiz.de/10005776661
In the United States, the Food and Drug Administration (FDA) provides public oversight of the safety and efficacy of drugs; medical devices; biologics like vaccines and blood products; cosmetics; radiation-emitting electronic products; veterinary products; and all foods, except meat and poultry...
Persistent link: https://www.econbiz.de/10005820082
Persistent link: https://www.econbiz.de/10005758629
No Abstract
Persistent link: https://www.econbiz.de/10005793133
Persistent link: https://www.econbiz.de/10005821914
Although the not-for-profit sector contributes greatly to aggregate output in many industries, there has been little explicit analysis of the economic consequences of applying antitrust policy in this sector. Despite the differences between for-profit and nonprofit firms stressed in conventional...
Persistent link: https://www.econbiz.de/10005834388
For decades, the US public and private sectors have committed substantial resources towards cancer research, but the societal payoff has not been well-understood. We quantify the value of recent gains in cancer survival, and analyze the distribution of value among various stakeholders. Between...
Persistent link: https://www.econbiz.de/10008499178
No Abstract
Persistent link: https://www.econbiz.de/10005694723
Given the rapid growth in health care spending that is often attributed to technological change, many private and public institutions are grappling with how to best assess and adopt new health care technologies. We argue that popular assessment criteria going under the rubric of...
Persistent link: https://www.econbiz.de/10005125915